Skip to main content
. Author manuscript; available in PMC: 2010 Jun 19.
Published in final edited form as: Immunity. 2009 Jun 4;30(6):875–887. doi: 10.1016/j.immuni.2009.05.005

Figure 4. IL-1β is required for murine disease.

Figure 4

(A) Nlrp3A350V/+/CreL and wildtype littermates were treated with subcutaneously injected mIL-1 Trap every other day beginning day 1–2 post-birth. Survival (left) (n=9) and growth (right) (n=2–9 mice), P=0.003 by log-rank (Mantel-Cox) comparison. (B) Survival (left) and growth (right) of Nlrp3A350V/+/CreL/Il-1r+/− and Nlrp3A350V/+/CreL/Il-lr−/−, (n=13–18 for survival and 1–9 for growth). (C) Survival (left) and growth (right) of Nlrp3L351P/+/CreL/Il-1r−/−, (n=33 for survival and 2–12 for growth). Error bars shown for mean daily weights on growth curves are SDev. (D) Luminex analysis of serum from Nlrp3A350V/+/CreL/Il-lr−/−, n=5, compared with Luminex data from WT and Nlrp3A350V/+/CreL in figure 2 (averages and SEM shown only).